and sCD8 were measured simultaneously in the sera which were stored at -20C.
Results and Discussion
As shown in Fig. 1 , the serum level of sCD4 showed no significant difference between RA patients and healthy controls, but that of sCD23 was significantly higher in all RA patients compared with controls. Concerning sCD8, these values were distributed in a wider range with a tendency that the majority of RA patients showed higher ones which were, as a whole, statistically no different from the controls. When the correlation of the level of sCD23 with that of each Ig subtype, CRP, or ESR was examined (Table 1) , no correlation was obtained between sCD23 and each Ig subtype, or between sCD23 and CRP. However, an insignificant but considerable correlation was shown between sCD23 and ESR. Considering the fact that CRP is well known as a more acute phase reactant than ESR, this finding suggests that the serum level of sCD23 might be taken as a parameter reflecting the immune activation in the chronic phase rather than the acute phase. On the other hand, the correlation between serum levels of sCD23 and IgM-RF was statistically significant (Fig. 2A) . These data confirm that sCD23 might play an important role on the specific production of IgM from RF-committed B cells.
A recent study has revealed that the sCD23 Fig. 1 ). We further performed a longitudinal study on the changes in the serum sCD23, sCD8, and IgM-RF levels in addition to classical inflammation parameters (CRP and ESR) in two patients during one year. The results are shown in Fig. 3 . In both cases, the serum levels of sCD23 were changing almost in parallel with that' of IgM-RF.
Comparing both cases, a changing pattern of sCD23 was correlated more closely to that of ESR than CRP. In contrast, time-related change of the serum level of sCD8 was also independent from that of sCD23 in this study as shown in the cross-sectional study described above. These observations might permit speculation that sCD23, but not sCD8, is taken as a more indicative marker reflecting the immune status of RA patients either in cross-section or longitudinal study.
